CHEK2 and ductal breast carcinoma in situ: The Breast Cancer Association Consortium reported the risk of 2.2 for DCIS in association with CHEK2 truncating variants, 0.8% of 4187 DCIS patients carried a CHEK2 truncating mutation [48].